Official Title
Collaborative Transplant Study (CTS) Pre- and Post-Transplantation Covid-19 Serum Studies: Antibody Development Following a SARS-CoV-2 Infection
Brief Summary

The Covid-19 Serum Study is a prospective case-control study in 1. kidney or liver transplanted patients being hospitalized due to an infection with Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) after transplantation (TX) (POST-TX Covid-19 Serum Study) or 2. patients receiving kidney or liver transplantation after having had a SARS-CoV-2 infection (PRE-TX Covid-19 Serum Study) The aim of this study is to evaluate the development of de novo donor specific antibodies (dnDSA) in transplanted patients being hospitalized due to an infection with SARS-CoV-2 (POST-TX Covid-19 Serum Study) as well as in patients receiving kidney or liver transplantation after having had an infection with SARS-CoV-2 prior to transplantation (PRE-TX Covid-19 Serum Study). Further, the investigators will evaluate possible consequences of having had a SARS-CoV-2 infection prior or after liver or kidney transplantation with regard to graft survival and incidence of graft rejection episodes as well as SARS-CoV-2 specific antibody development after SARS-CoV-2 infection.

Unknown status
COVID19
Kidney Transplant; Complications
Kidney Transplant Failure and Rejection
Liver Transplant; Complications
Liver Transplant Failure and Rejection
Eligibility Criteria

Inclusion Criteria:

- Kidney-transplant recipients and full-size liver-recipients (de-novo or
re-transplanted)

- Participant or legal guardian is willing and able to give informed consent for
participation in the trial

- SARS-CoV-2 infection before transplantation (PRE-TX Covid-19 Serum Study) or after
transplantation (POST-TX Covid-19 Serum Study)

Specific Inclusion Criteria for PRE-TX Covid-19 Serum Study:

- Kidney or liver transplantation between Dec 17,2020 - Dec 17, 2021

Specific Inclusion Criteria for POST-TX Covid-19 Serum Study:

- Hospitalization due to SARS-CoV-2 infection in between Dec 17,2020 - Dec 17, 2021

Exclusion Criteria:

- Participants not meeting the inclusion criteria

- multi-organ transplant recipients

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 75 Years
Countries
Germany
Locations

Nierenzentrum Heidelberg
Heidelberg, DE, Germany

Investigator: Christian Morath, Professor
Contact: +49 (0)6221-91120
christian.morath@med.uni-heidelberg.de

Investigator:

Contacts

Caner Suesal, Professor
+49 (0) 6221 56-5545
caner.suesal@med.uni-heidelberg.de

Christian Morath, Professor
+49 (0) 6221 91120
christian.morath@med.uni-heidelberg.de

Heidelberg University
NCT Number
Keywords
Covid-19
SARS-CoV-2
Kidney transplantation
Liver transplantation
donor-specific antibodies
dnDSA
MeSH Terms
COVID-19